Bone density in breast cancer: when to intervene?
Gralow
Julie R
JR
D015502:Absorptiometry, Photon; D000077384:Anastrozole; D000970:Antineoplastic Agents / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D047072:Aromatase Inhibitors / Q000009:adverse effects; D015519:Bone Density / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D017273:Goserelin / Q000009:adverse effects; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D009570:Nitriles / Q000009:adverse effects; D010024:Osteoporosis / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D013629:Tamoxifen / Q000009:adverse effects; D014230:Triazoles / Q000009:adverse effects; D000077211:Zoledronic Acid
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004164:Diphosphonates; D007093:Imidazoles; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D017273:Goserelin; D000077384:Anastrozole; D000077211:Zoledronic Acid